Zrubka Zsombor, Rashdan Omar, Gulácsi László
Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary.
Doctoral School of Business and Management, Corvinus University of Budapest, Budapest, Hungary.
Glob J Qual Saf Healthc. 2020 Jun 8;3(2):44-54. doi: 10.36401/JQSH-20-4. eCollection 2020 May.
We reviewed the scope of countries, diseases, technologies, and methods involved in the health economic evaluations published in the Middle East and North Africa (MENA) region.
PRISMA guidelines were followed. A PubMed search was conducted up to December 15, 2019. English language full-text articles were included if they reported original research on humans; involved the local population from Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates, or Yemen; reported costs; and involved a full or partial health economic analysis comparing alternative health technologies. Data on publication year, country of origin, disease area according to ICD-10, type of health technology, and applied methods were extracted.
From 105 eligible articles, 57.1% were published between 2015 and 2019. Egypt (30.5%) and Saudi Arabia (27.6%) were the most frequently involved countries. Infectious diseases were most often studied (27.6%). The assessed technology was a system (eg, infection control, screening, coverage/access, hospital management, or healthcare delivery program) in 41.9% of studies. Cost-utility analysis (CUA) was the most frequent method (29.5%) and was growing rapidly. Health system perspective was adopted in 52.4% of studies, whereas societal perspective was scarce (8.6%). The majority of studies (46.7%) were published in Scimago Q1 journals. Over half of the studies (54.2%) did not report or did not have a funding source.
From 2015, health economic analysis became more frequent in the MENA region, providing input to value-based health policy and financing. For further growth, in addition to the development of the institutional background, valid and more standardized local cost and outcome data should be available.
我们回顾了中东和北非（MENA）地区发表的卫生经济评估所涉及的国家范围、疾病、技术和方法。
遵循PRISMA指南。截至2019年12月15日进行了PubMed检索。如果英文全文文章报告了关于人类的原始研究；涉及来自阿尔及利亚、巴林、埃及、伊拉克、约旦、科威特、黎巴嫩、利比亚、摩洛哥、阿曼、巴勒斯坦、卡塔尔、沙特阿拉伯、叙利亚、突尼斯、阿拉伯联合酋长国或也门的当地人群；报告了成本；并且涉及比较替代卫生技术的全部或部分卫生经济分析，则纳入这些文章。提取了关于发表年份、原产国、根据ICD - 10分类的疾病领域、卫生技术类型和应用方法的数据。
在105篇符合条件的文章中，57.1%是在2015年至2019年期间发表的。埃及（30.5%）和沙特阿拉伯（27.6%）是最常涉及的国家。传染病是最常被研究的（27.6%）。在41.9%的研究中，评估的技术是一个系统（例如，感染控制、筛查、覆盖/可及性、医院管理或医疗服务提供项目）。成本效用分析（CUA）是最常用的方法（29.5%）并且增长迅速。52.4%的研究采用了卫生系统视角，而社会视角较少（8.6%）。大多数研究（46.7%）发表在Scimago Q1期刊上。超过一半的研究（54.2%）没有报告或没有资金来源。
从2015年起，卫生经济分析在MENA地区变得更加频繁，为基于价值的卫生政策和融资提供了依据。为了进一步发展，除了发展机构背景外，还应提供有效且更标准化的当地成本和结果数据。
